Osteoporozlu Hastalarda Kardiyovasküler Riskin Yeniden Değerlendirilmesi: Kişiselleştirilmiş Romosozumab Tedavisinin Önemi
PDF

Editöre Mektup

Osteoporozlu Hastalarda Kardiyovasküler Riskin Yeniden Değerlendirilmesi: Kişiselleştirilmiş Romosozumab Tedavisinin Önemi

Turk J Osteoporos 2025;31(3):205-206 DOI: 10.4274/tod.galenos.2025.16870
, , , ,
PDF
İzin

Kaynakça

1

Reid IR. What is the risk of cardiovascular events in osteoporotic patients treated with romosozumab. Expert Opin Drug Saf. 2022;21:1441-3.

2

Stokar J, Szalat A. Cardiovascular safety of romosozumab vs PTH analogues for osteoporosis treatment: a propensity-score-matched cohort study. J Clin Endocrinol Metab. 2025;110:e861-7. Erratum in: J Clin Endocrinol Metab. 2025;110:e915.

3

Vestergaard Kvist A, Faruque J, Vallejo-Yagüe E, Weiler S, Winter EM, Burden AM. Cardiovascular safety profile of romosozumab: a pharmacovigilance analysis of the US food and drug administration adverse event reporting system (FAERS). J Clin Med. 2021;10:1660.

4

Alnaqbi KA, Al Zeyoudi J, Aljaberi AK. Cardiac arrhythmia and heart failure shortly after starting romosozumab for osteoporosis: a case-based review. Cureus. 2023;15:e50303. Erratum in: Cureus. 2023;15:c148.